Deinove (ALDEI)

Business description

Deinove is a biotech company that discovers, develops and manufactures compounds of industrial interest stemming from rare bacteria and intended for the health, nutrition and beauty markets.

Growing towards commercialisation

Update | Alternative Energy | 01/04/2015

Business expansion increased short term losses in FY14. However the longer term prospects are more important and in FY14 Deinove made progress on both the scientific and commercial fronts. We now expect commercial revenue from 2017 and although Deinove has sufficient funds to last until Q316, we anticipate that it will seek additional funding in FY15.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Stock data

Market cap.€19.6m
Last close€1.802
High / Low (52 weeks)€2.2 / €1.6
Stock market listingEG
Forecast net debt (€m)5.1
Forecast gearing ratio (%)2716
TeamIndustrials
SectorAlternative Energy

Price performance

%1m3m12m
Actual6.6(1)(20.3)
Relative *3.5(3.5)(30.4)

* % Relative to local index

Company news